Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.08 USD | -0.34% | -3.86% | -12.77% |
Jun. 03 | UroGen Pharma Appoints David Lin as New Chief Commercial Officer | CI |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
Chart: Technical Analysis
Technical analysis trends
Short Term | Mid-Term | Long Term | |
---|---|---|---|
Trend | Neutral | Bearish | Neutral |
Resistance | 14.53 | 15.10 | 22.61 |
Spread/Res. | -9.94% | -13.34% | -42.13% |
Spread/Supp. | +2.71% | +2.71% | +42.38% |
Support | 12.74 | 12.74 | 9.190 |
Technical Rankings Surperformance
Short Term Timing | |
---|---|
Middle Term Timing | |
Long Term Timing | |
RSI | |
Bollinger Spread | |
Unusual Volumes |
- Stock Market
- Equities
- URGN Stock
- Charts UroGen Pharma Ltd.